Immunocore Holdings plc (NASDAQ:IMCR) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its stake in Immunocore Holdings plc (NASDAQ:IMCR) by 59.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,538 shares of the company’s stock after selling 6,737 shares during the period. JPMorgan Chase & Co.’s holdings in Immunocore were worth $141,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of IMCR. Envestnet Asset Management Inc. raised its stake in Immunocore by 0.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company’s stock worth $2,392,000 after acquiring an additional 606 shares in the last quarter. Millennium Management LLC increased its position in shares of Immunocore by 124.4% during the second quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after purchasing an additional 333,167 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Immunocore by 37.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 121,753 shares of the company’s stock valued at $4,126,000 after purchasing an additional 33,003 shares during the last quarter. Connective Portfolio Management LLC acquired a new stake in shares of Immunocore in the 3rd quarter valued at about $218,000. Finally, Exchange Traded Concepts LLC grew its stake in Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

NASDAQ IMCR opened at $32.88 on Friday. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -34.61 and a beta of 0.76. The business’s 50 day moving average is $30.55 and its two-hundred day moving average is $33.11. Immunocore Holdings plc has a 12-month low of $27.69 and a 12-month high of $76.98. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter in the prior year, the company posted ($0.59) earnings per share. Immunocore’s quarterly revenue was up 23.7% on a year-over-year basis. Research analysts expect that Immunocore Holdings plc will post -0.94 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on IMCR. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday, January 27th. UBS Group began coverage on shares of Immunocore in a research note on Thursday, October 24th. They set a “sell” rating and a $24.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $71.00 price target on shares of Immunocore in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.